Monoclonal Antibody Precision Therapy Targeting Inflammation for Bipolar Disorder: a Narrative Review

Overview

Journal Ther Adv Psychopharmacol

Specialty Psychiatry

Date 2024 Feb 7

PMID 38322010

Authors

Shijin Wu

Yuyang Zhou

Affiliations

Soon will be listed here.

Abstract

Bipolar disorder (BD) is a severe mental disorder with various hypotheses regarding its pathogenesis. This article provides a summary of numerous studies on the variations in inflammatory cytokine levels in patients with BD and the effects of treatment with antipsychotics, mood stabilizers, and antidepressants on these levels. In addition, patients with autoimmune diseases who use anti-inflammatory monoclonal antibodies experience symptoms, such as depression, anxiety, and insomnia. These pieces of evidence suggest a potential association between immune inflammation and BD and offer new possibilities for therapy. Building upon this relationship, the authors propose an innovative approach for treating BD through individualized and precise therapy using anti-inflammatory monoclonal antibody drugs. To support this proposal, the authors compile information on pharmacological effects and relevant studies, including trials of various anti-inflammatory therapeutic monoclonal antibody drugs (e.g. infliximab, tocilizumab, and canakinumab) for the potential treatment of BD and its associated side effects in psychiatry. The authors categorize these anti-inflammatory monoclonal antibody drugs into levels I-IV through a comprehensive analysis of their advantages and disadvantages. Their potential is examined, and the need for further exploration of their pharmaceutical effects is established.

References

Husain M, Chaudhry I, Khoso A, Husain M, Hodsoll J, Ansari M . Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry. 2020; 7(6):515-527. DOI: 10.1016/S2215-0366(20)30138-3. View

Hodes G, Menard C, Russo S . Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiol Stress. 2016; 4:15-22. PMC: 5146277. DOI: 10.1016/j.ynstr.2016.03.003. View

Smith J, Das A, Ray S, Banik N . Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull. 2011; 87(1):10-20. PMC: 9827422. DOI: 10.1016/j.brainresbull.2011.10.004. View

Ouyang W, OGarra A . IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity. 2019; 50(4):871-891. DOI: 10.1016/j.immuni.2019.03.020. View

Lotrich F, Butters M, Aizenstein H, Marron M, Reynolds 3rd C, Gildengers A . The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry. 2013; 29(6):635-44. PMC: 4013203. DOI: 10.1002/gps.4048. View

Modabbernia A, Taslimi S, Brietzke E, Ashrafi M . Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013; 74(1):15-25. DOI: 10.1016/j.biopsych.2013.01.007. View

Prieto G, Tong L, Smith E, Cotman C . TNFα and IL-1β but not IL-18 Suppresses Hippocampal Long-Term Potentiation Directly at the Synapse. Neurochem Res. 2018; 44(1):49-60. PMC: 6170724. DOI: 10.1007/s11064-018-2517-8. View

Heo Y . Satralizumab: First Approval. Drugs. 2020; 80(14):1477-1482. PMC: 7522096. DOI: 10.1007/s40265-020-01380-2. View

Raison C, Rutherford R, Woolwine B, Shuo C, Schettler P, Drake D . A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2012; 70(1):31-41. PMC: 4015348. DOI: 10.1001/2013.jamapsychiatry.4. View

10.

Aronica R, Enrico P, Squarcina L, Brambilla P, Delvecchio G . Association between Diffusion Tensor Imaging, inflammation and immunological alterations in unipolar and bipolar depression: A review. Neurosci Biobehav Rev. 2022; 143:104922. DOI: 10.1016/j.neubiorev.2022.104922. View

11.

Leonard B . The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25(4):767-80. DOI: 10.1016/s0278-5846(01)00155-5. View

12.

Munkholm K, Weikop P, Kessing L, Vinberg M . Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain Behav Immun. 2014; 43:205-13. DOI: 10.1016/j.bbi.2014.09.021. View

13.

Kokkosis A, Tsirka S . Neuroimmune Mechanisms and Sex/Gender-Dependent Effects in the Pathophysiology of Mental Disorders. J Pharmacol Exp Ther. 2020; 375(1):175-192. PMC: 7569311. DOI: 10.1124/jpet.120.266163. View

14.

Aftab A, Kemp D, Ganocy S, Schinagle M, Conroy C, Brownrigg B . Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. J Affect Disord. 2019; 245:957-964. DOI: 10.1016/j.jad.2018.11.090. View

15.

Munkholm K, Brauner J, Kessing L, Vinberg M . Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013; 47(9):1119-33. DOI: 10.1016/j.jpsychires.2013.05.018. View

16.

McIntyre R, Subramaniapillai M, Lee Y, Pan Z, Carmona N, Shekotikhina M . Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019; 76(8):783-790. PMC: 6506894. DOI: 10.1001/jamapsychiatry.2019.0779. View

17.

Tang G, Chen P, Chen G, Zhong S, Gong J, Zhong H . Inflammation is correlated with abnormal functional connectivity in unmedicated bipolar depression: an independent component analysis study of resting-state fMRI. Psychol Med. 2021; :1-11. DOI: 10.1017/S003329172100009X. View

18.

Saccaro L, Crokaert J, Perroud N, Piguet C . Structural and functional MRI correlates of inflammation in bipolar disorder: A systematic review. J Affect Disord. 2023; 325:83-92. DOI: 10.1016/j.jad.2022.12.162. View

19.

Morgan J, Singhal G, Corrigan F, Jaehne E, Jawahar M, Baune B . TNF signalling via the TNF receptors mediates the effects of exercise on cognition-like behaviours. Behav Brain Res. 2018; 353:74-82. DOI: 10.1016/j.bbr.2018.06.036. View

20.

Tiosano S, Yavne Y, Watad A, Langevitz P, Lidar M, Feld J . The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis. Eur J Clin Invest. 2020; 50(9):e13268. DOI: 10.1111/eci.13268. View